Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25381191 | 1.00 | ESR2 (0.46) | ESR2SCN9ANR1H2MAPK1UCHL1 | |
| SCHEMBL17686937 | 0.89 | UCHL1 (0.49) | ESR2SCN9ANR1H2MAPK1UCHL1 | |
| SCHEMBL16269155 | 0.89 | UCHL1 (0.49) | ESR2SCN9ANR1H2MAPK1UCHL1 | |
| SCHEMBL16269377 | 0.89 | ADORA1 (0.45) | ESR2SCN9ANR1H2MAPK1UCHL1 | |
| SCHEMBL16269378 | 0.89 | ADORA1 (0.45) | ESR2SCN9ANR1H2MAPK1UCHL1 | |
| SCHEMBL22319906 | 0.85 | ABHD6 (0.40) | ABHD6MAPTKDM4E | |
| SCHEMBL29554774 | 0.84 | ESR2 (0.52) | ESR2SCN9ANR1H2MAPK1UCHL1 | |
| SCHEMBL5880442 | 0.84 | ESR2 (0.52) | ESR2SCN9ANR1H2MAPK1UCHL1 | |
| SCHEMBL30678892 | 0.83 | UCHL1 (0.48) | ESR2SCN9ANR1H2MAPK1UCHL1 | |
| SCHEMBL25381833 | 0.83 | UCHL1 (0.48) | ESR2SCN9ANR1H2MAPK1UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833162-B2 | Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2023-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833162-B2 | Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same | C1R, F12, RDX | ESR2 1328/4885SCN9A 4001/4885NR1H2 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.